SanaCurrents on Syndax's rising drug to treat rare, acute leukemias | $SNDX
...advancing the small molecule revumenib to become a backbone treatment for rare forms of acute leukemia
SUMMARY
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is advancing the small molecule revumenib to become a backbone treatment for rare forms of acute leukemia. The specific types of rare leukemia are identified by a genetic signature and can be diagnosed through a lab test.
Oral revumenib attempts to inhibit the locus between the protein menin and the mixed lineage leukemia (MLL) gene. Results from a 68-patient, phase I trial announced in December 2022 indicated a 53% overall response rate (ORR) for revumenib across several forms of rare leukemias. The company expects to release phase II revumenib data to treat versions of MLL, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in the third quarter of 2023.
Next Key catalysts
Topline phase II data from revumenib to treat AML and ALL
Key catalyst dates
Q3 2023